2026-05-27T12:12:49Zhttps://riuma.uma.es/rest/oai/requestoai:riuma.uma.es:10630/287312026-02-03T11:14:27Zcom_10630_2254col_10630_37953
Hormigo-Pozo, Antonio Eduardo
Torres-Ortega, Desireé
García-Ruiz, Antonio J.
Escribano-Serrano, José
Escribano Cobalea, María
García-Agua-Soler, Nuria
2024-01-15T11:50:12Z
2024-01-15T11:50:12Z
2023-10-17
Antonio Hormigo Pozo, Desireé Torres Ortega, Antonio J. García Ruiz, José Escribano Serrano, María Escribano Cobalea, Nuria García-Agua Soler, Approach to patients with diabetes and obesity in primary care, Atención Primaria, Volume 56, Issue 2, 2024, 102807, ISSN 0212-6567, https://doi.org/10.1016/j.aprim.2023.102807.
https://hdl.handle.net/10630/28731
10.1016/j.aprim.2023.102807
Aims:
The
aim
of
this
study
is
to
analyse
the
effect
of
pharmacological
and
non-pharmacological
treatment
on
weight
control
in
patients
with
diabetes
and
obesity.
Design:
Epidemiological,
descriptive,
cross-sectional
study.
Site:
Primary
care.
In
11
health
centres
in
Málaga
and
Cádiz
during
April
and
October
2022.
Participants:
281
patients
over
18
years
old
with
type
2
diabetes
and
obesity
are
included.
Main
measurements:
Socio-demographics,
clinical,
treatment
and
lifestyle
habits
variables
were
obtained
from
medical
records
and
personal
interview.
Descriptive
statistics
were
obtained
for
continuous
variables.
Statistical
tests
were
performed
based
on
the
nature
of
the
variables.
Results:
Variables
like
marital
status,
level
of
education
and
occupation,
and
smoking
habit,
shows
differences
regarding
the
sex
(
p
<
0.05).
82.3%
of
those
who
received
education
lost
weight,
compared
to
67.5%
of
lost
weight
who
received
no
health
education
(
p
=
0.004).
GLP1
and
SGLT2
were
more
commonly
prescribed
for
women
(
p
=
0.048),
and
SGLT2
more
commonly
prescribed
for
men
(
p
=
0.047).
Patients
taking
GLP1,
SGLT2
or
both,
regardless
of
sex,
weight
loss
during
the
study
period
was
−
3.1
kg
(SE:
0.60),
while
the
loss
of
those
who
took
other
medications
was
−
1.33
kg
(SE:
0.62).
The
mean
difference
was
1.75
kg
(
p
=
0.046).
Conclusions:
In
terms
of
weight
loss,
obese
diabetics
who
took
GLP1,
SGLT2
or
both
were
2.5
times
more
likely
to
lose
weight
than
those
who
did
not.
Healthy
lifestyle
choices
are
key
to
weight
loss
in
obese
diabetic
patients
eng
http://creativecommons.org/licenses/by/4.0/
open access
Atribución 4.0 Internacional
Obesidad
Diabetes
Atención primaria
Farmacología
Approach to patients with diabetes and obesity in primary care
journal article